New hope for advanced kidney cancer patients in early drug trial
Disease control
Recruiting now
This early-stage study is testing the safety and best dose of a new drug, HC-7366, when given alongside an approved kidney cancer drug, belzutifan. It will enroll about 80 adults with advanced kidney cancer that has spread or cannot be removed by surgery. The main goal is to find…
Phase: PHASE1 • Sponsor: HiberCell, Inc. • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC